Other studies have correlated the upregulation of neuroserpin that, together with the decreased expression of tPA, has been observed at advanced stages of amyloid pathology in AD patients and in a transgenic rat model of AD, with dysregulation of the nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) metabolic pathways [140, 141]. The gene discussed is NGF; the disease is Alzheimer disease.